Horowitz Group

Vibrato Medical is creating a noninvasive treatment for Critical Limb Ischemia and Peripheral Arterial Disease in order to increase tissue perfusion, alleviate symptoms, and save limbs. Based on decades of study and the most recent advances in ultrasound technology, our gadget is the first wearable therapeutic ultrasound designed to stimulate vasodilation and vessel development.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, that specializes in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions. Its primary focus is on TP-03, a novel treatment currently in Phase IIb/III trials for blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. The company is also advancing additional candidates, including TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and community malaria reduction. Tarsus aims to address significant unmet medical needs in various therapeutic areas, initially concentrating on eye care where treatment options are limited. Founded in 2016, Tarsus Pharmaceuticals continues to expand its pipeline to include diverse diseases across different medical fields.

Metavention develops new treatment that is intended to permanently disrupt the overactive nerves that cause high blood pressure and other metabolic diseases. They offer a renal denervation procedure that delivers radio frequency energy to targeted overactive sympathetic nerves using their IRF denervation system.

Miniluxe operates as a nail and beauty lounge that offers manicures, pedicures, warm oil treatment, waxing, and hands and feet therapies. It was founded in 2006 and is headquartered in Boston, Massachusetts.